PUBLIC TITLE ; Effect of niacin on hyperphosphatemia in chronic kidney disease (stages 3-5) patients

Effect of niacin on hyperphosphatemia in chronic kidney disease (stages 3-5) patients. A randomized double blind placebo controlled trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR201905507865682

Enrollment

120

Registered

2019-05-06

Start date

2019-04-29

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

niacin

placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria CKD stages 3-5 patients who are aged 18 years -80 years. Capable of giving informed consent Serum phosphate levels 5-7 mg/dl Unchanged treatment protocol (calcium carbonate and vitamin D) during last 2 weeks.

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study. Pregnancy Known liver disease, Active peptic ulcer disease Necessity of changing treatment protocol because of safety criteria (such as severe hyperphosphatemia or two consecutive serum phosphorus levels > 7 mg/dl) Age greater than 80 years

Design outcomes

Primary

Measure	Time frame
mean change in serum phosphate levels from first to last week	—

Secondary

Measure	Time frame
Secondary outcome Mean change in calcium, calcium-phosphate products and lipid profile parameters (HDL,LDL,TRYGLICERIDES	—

Countries

Nigeria

Contacts

Public ContactChigozie;Chigozie Offiah;Offiah

Research Assistant;Research Assistant

offiahchigozie@gmail.com;offiahchigozie@gmail.com+2348067668353;+2348067668353

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026